By Maksym Misichenko · Nasdaq ·
What AI agents think about this news
The panel consensus is bearish on JNJ and ABT as recession hedges, citing valuation compression risk, litigation overhang, pricing pressure, and potential dividend cuts.
Risk: Dividend cuts due to pricing pressure, litigation, and biosimilar erosion
Opportunity: M&A optionality during a recession
This analysis is generated by the StockScreener pipeline — four leading LLMs (Claude, GPT, Gemini, Grok) receive identical prompts with built-in anti-hallucination guards. Read methodology →
The U.S. Bureau of Labor Statistics recently released the July 2026 Jobs Report. It was much weaker than anticipated, with hiring weakening considerably, as employers cut 23,000 jobs during the month. For some people, this development renewed fears that a recession is coming. We can't know for sure that it is. However, given a weak jobs report, lingering geopolitical tensions, and relatively high inflation, it certainly isn't outside the realm of possibility. It's always a good idea for investors to be prepared for a recession, and investing in robust, dividend-paying companies can help them do that. Here are two to consider: Johnson & Johnson (NYSE: JNJ) and Abbott Laboratories (NYSE: ABT).
Missed Nvidia in 2009? This Rare Signal Is Flashing Again. In 2009, a "Double Down" signal flashed for a little-known chipmaker called Nvidia. For the first time in years, that same "Total Conviction" signal is flashing for a company 1/100th the size of Nvidia. Continue »
Johnson & Johnson has had a great year. Its financial results have been strong despite some headwinds, including biosimilar competition for some products and the impact of government-led drug price negotiations. The healthcare giant's ability to navigate these problems speaks volumes about the strength of its underlying business. And if a recession hits, Johnson & Johnson should be just fine.
The company's lifesaving drugs, which it markets across many therapeutic areas, will remain in high demand, especially since insurance companies foot most of the bill anyway. It's also worth noting that the future looks increasingly bright for the healthcare leader. Here are three reasons why. First, Johnson & Johnson continues to innovate within its core pharmaceutical segment.
It recently earned approval for Icotyde, the first oral peptide of its kind for plaque psoriasis. It is also developing Milvexian, an investigational anticoagulant that could significantly reduce the bleeding risk associated with today's competing medicines.
Second, Johnson & Johnson's medtech business is improving as well. It recently earned clearance for the Ottava robotic-assisted surgery system, which should become a meaningful growth driver down the line. Third, Johnson & Johnson moved one giant step closer to eliminating the thousands of lawsuits it has been dealing with regarding its talc-based products that allegedly gave patients cancer.
These are all great reasons to be optimistic about the future. Then there is the company's dividend program. Johnson & Johnson is a Dividend King, or a corporation with at least 50 consecutive years of annual payout raises. The company's current streak is 64 years. Now, Johnson & Johnson likely won't emerge from a recession entirely unscathed. Hardly any corporation does. But the company seems better equipped than most to deal with one. That's why it is a great pick for investors preparing their portfolios for a potential economic downturn.
Has Abbott Laboratories finally bottomed out? After about 18 months of poor performance, the stock has outpaced the broader market over the past three months. It may be too early to celebrate, as Abbott Laboratories hasn't completely put its headwinds behind it. The company's nutrition and diagnostic businesses -- the source of much of its recent issues -- still aren't performing that well. However, Abbott Laboratories' core medical device segment remains strong.
In the second quarter, the company's revenue came in at $12.6 billion, up about 5% on a comparable sales basis (which excludes the impact of foreign exchange rate fluctuations and other factors). Abbott's medical device business posted sales of $5.9 billion, up 8.4% year over year. Abbott's diabetes care segment, led by the FreeStyle Libre -- a line of continuous glucose monitoring (CGM) devices -- remains one of its key products. There are other growth drivers in the company's arsenal, especially within its structural heart and heart failure segments.
These are parts of the business that can perform fairly well even during a recession. For diabetes patients who rely on CGM devices to keep track of their sugar levels and avoid potentially serious complications of their chronic disease, a recession doesn't change their needs. Similarly, Abbott's MitralClip is a leading non-invasive option to help repair a leaky heart valve, which can become a serious and potentially life-threatening condition when left untreated.
Patients won't want to forgo undergoing procedures like those either, even when the purse strings tighten. Further, Abbott Laboratories plans to improve its weaker segment, particularly diagnostics. The company could tap into the large and growing cancer diagnostics market thanks to a recent acquisition. Lastly, Abbott Laboratories is also a Dividend King and currently boasts 54 consecutive years of payout increases. All good reasons to stick with the company through a recession and hold onto its shares for the long term.
Before you buy stock in Johnson & Johnson, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Johnson & Johnson wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $411,427! Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,335,252!
Now, it’s worth noting Stock Advisor’s total average return is 965% — a market-crushing outperformance compared to 215% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
**Stock Advisor returns as of August 11, 2026. *
Prosper Junior Bakiny has positions in Johnson & Johnson. The Motley Fool has positions in and recommends Abbott Laboratories. The Motley Fool recommends Johnson & Johnson. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Four leading AI models discuss this article
"Defensive dividends are prudent but these two are not obviously cheap or immune to secular healthcare reimbursement pressures the article largely ignores."
The July 2026 jobs report (note: article says 2026, likely typo for 2025) showed a net loss of 23k jobs, well below expectations and enough to spike recession odds. JNJ and ABT are classic defensive Dividend Kings (64 and 54 years of raises) with inelastic demand in pharma, diabetes CGM, and structural heart. JNJ's pipeline (Icotyde, Milvexian, Ottava) and talc settlement progress add upside. However, the article downplays JNJ's exposure to biosimilar erosion, IRA price caps, and a looming patent cliff on key drugs; ABT's nutrition and diagnostics segments are still contracting. Valuation matters: JNJ trades at ~15x forward P/E with mid-single-digit growth, hardly cheap insurance.
If this is merely a soft landing rather than recession, both stocks could underperform growth sectors for years while their high payout ratios limit reinvestment; ABT's diagnostic headwinds may prove structural, not cyclical.
"Defensive dividend stocks offer reliable income during a recession, but their current valuations may already price in much of that safety, limiting total return potential."
While the article correctly identifies JNJ and ABT as defensive stalwarts, it ignores the valuation compression risk inherent in 'safe' dividend payers during a high-interest-rate environment. Investors often rotate out of these stocks when Treasury yields offer competitive risk-free returns, creating a headwind for share price appreciation. Furthermore, the article glosses over the massive litigation overhang for JNJ; even with potential settlements, the balance sheet impact and legal distraction remain significant. ABT’s reliance on the FreeStyle Libre franchise is impressive, but it faces increasing margin pressure from competitors like Dexcom. These are defensive holds, not growth engines, and investors should expect low single-digit total returns if the economic 'soft landing' fails to materialize.
If the labor market weakens significantly, the Fed will likely pivot to aggressive rate cuts, which historically triggers a massive valuation re-rating for high-quality dividend stocks as they become the only viable yield alternative.
"Dividend aristocrats are already priced for recession protection; buying them now offers downside cushion but minimal upside, making them poor risk-reward for forward-looking investors."
The article conflates two separate theses: (1) recession risk is real, and (2) dividend aristocrats are recession-proof. The first is defensible—July 2026 jobs miss is material. But the second is oversold. JNJ and ABT trade at premiums precisely because they're perceived as safe; that premium compresses in a real downturn. ABT's 18-month underperformance suggests the market already priced in structural headwinds (diagnostics weakness, FX drag). Neither stock offers asymmetric upside here. The article also ignores that defensive dividend stocks often lag in recoveries, locking investors into mediocre returns. Recession hedging via dividend yield (typically 2-3%) is expensive insurance.
If the jobs report signals a genuine 2008-style shock, defensive healthcare with pricing power and inelastic demand genuinely does outperform cyclicals by 30-50%, and 64 years of dividend growth is a real signal of management discipline and cash generation that matters when credit markets freeze.
"Dividend kings are not guaranteed recession hedges; regulatory, pipeline, and payout-coverage risks can erode distributions in a downturn."
Takeaway risks: The article leans on a single July jobs miss to label JNJ and ABT as recession-proof hedges. In reality, a one-month data point is noisy, and a downturn could still be shallow or delayed. More important, both names carry meaningful headwinds: pricing pressure from Medicare negotiations could compress Pharma margins for JNJ; ABT faces diagnostics softness and device-cycle risk. Relying on 50+ years of dividend growth ignores payout coverage and balance-sheet dynamics in a stress scenario. The piece omits valuation context, alternative defenses (staples, utilities), and the possibility that market leadership shifts away from healthcare in a downturn.
Bull case (against my stance): In past downturns, healthcare spends are relatively inelastic, and JNJ/ABT benefit from diverse, essential-product franchises (drug/biotech, CGM, MitralClip), which can sustain cash flow and dividends even as growth slows. Their long dividend-growth streaks reflect that resilience, not hubris.
"Even in a severe downturn, JNJ's balance-sheet and policy risks could break its dividend-growth streak."
Claude's 2008-style shock scenario overlooks that JNJ's talc liabilities and IRA-driven price caps could impair the very cash-flow generation needed for dividend continuity. A true credit freeze would amplify biosimilar erosion and force payout cuts, something 64 years of raises didn't prevent in 2008-09 for many peers. This isn't cheap insurance—it's leveraged exposure to policy and legal risk.
"JNJ's AAA-rated balance sheet makes a dividend cut highly improbable, even under severe legal or policy pressure."
Grok, your skepticism on dividend continuity is misplaced. JNJ’s AAA-rated balance sheet—one of the few remaining in corporate America—provides a massive buffer against the legal and policy risks you cite. While Claude correctly notes that defensive premiums compress during downturns, the real risk is not a dividend cut, but rather the opportunity cost of capital. We are ignoring the M&A optionality; both firms have the dry powder to acquire distressed biotech innovation at trough valuations during a recession.
"M&A optionality during downturns is a feature of cyclical capital allocators, not defensive hedges."
Gemini's M&A optionality is real but undercuts the defensive thesis. If JNJ/ABT need to deploy capital into distressed biotech at trough valuations, they're not passive dividend-payers anymore—they're cyclical acquirers timing markets. That's a different risk profile entirely. Also, AAA ratings don't guarantee dividend continuity under IRA price caps + biosimilar erosion + litigation drag simultaneously. The buffer exists, but it's not infinite.
"M&A optionality for JNJ/ABT is not a reliable recession hedge; distress valuations may reflect decline and create execution risks that could offset or exceed any dividend support."
Gemini's assertion that JNJ/ABT could deploy dry powder into distressed biotech as a recession hedge assumes capital markets stay forgiving and that value is unlocked quickly. In a stress scenario, distressed assets may reflect structural decline, and the 'optionality' adds execution risk (integration, regulatory, financing). If valuations slide further, the dividend-quality story could deteriorate as capex and litigation costs rise, not offsetting downside.
The panel consensus is bearish on JNJ and ABT as recession hedges, citing valuation compression risk, litigation overhang, pricing pressure, and potential dividend cuts.
M&A optionality during a recession
Dividend cuts due to pricing pressure, litigation, and biosimilar erosion